Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Laboratories Inc.

www.abbott.com

Latest From Abbott Laboratories Inc.

Diabetes, Mitral Repair And Diagnostics Drive Big Quarter For Abbott

Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.

Commercial Sales & Earnings

Abbott Sees Little Impact From Chinese Tenders

Competitive procurement practices for off-patent molecules in China are not affecting Abbott adversely because its local Established Pharmaceuticals portfolio is focused on niche, hard-to-make branded generics.

China Business Strategies

Abbott Inks Partnership With Tandem Diabetes Care

Abbott signed a deal with Tandem Diabetes Care to develop diabetes solutions to combine Abbott's glucose-sensing technology with Tandem's insulin delivery systems.

Diabetic Care Commercial

Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
Rare Diseases Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register